TRIMAG (Szwed) 2001

1 Treatments

Studied treatment

Control treatment

Concomitant treatments -

2 Patients

Patients -

Inclusion criteria -

Exclusion criteria -

symptomatic -

3 Methods

Blinding -

Design -

Centers -

Geographical area -

Sizes -9/-9

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dropouts due to adverse events</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Adverse events</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>

5 References